2Salem AM, Zohny SF, Abd El-Walab MM, et al. Predictive value of osteocalcin and beta-Crosslaps in metastatic breast cancer[ J]. Clin Bio- chem, 2007, 40(4): 1201-1208.
3Takahashi S. Evaluation of cancer-induced bone diseases by bone metabolic marker[J]. Clin Calcium, 2006,16(2) : 581-590.
5Jung K, Lein M, Stephan C, et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and progllosfie implieatlons[J], hit J Cancer, 2004, 111 (5) : 783-791.
6Brasso K, Christensen IJ, Johansen JS, et al. Prognostic value of PINP, bone alka)ine phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma[J]. Prostate, 2006, 66(5) : 503-513.
7Koopmans N, De Jong I, Breeuwsma A, et al. Serum bone turnover markers ( PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: A lougltudittal approach[ J ]. J Urol, ?2007, 178(3 ptl) :849-853.
8Koizumi M, Yonese J, Fukui I, et al. The serum level of the amino- terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone[J]. BJU hat, 2001, 87(4) : 348-351.
9Pollm,,un D, Siepmann S. The amino-terminal propeptide (PINP) of type 1 collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer [ J ]. Anficaneer Res, 2007,27(4A) :1853-1862.
10Lorente JA, Valenzuela H, Morote J, et al. ~rum bone alkalinephosphatase levels enhance the clinical utility of prostate specific; antigen in the staging of newly diagnosed prostate cancer patients [ J ]. Eur Nutl Med, 1999, 26(6) :625-632.
3Koizumi M, Ogata E. Bone metabolic markers as gauges of metastasis to bone:a review [J]. Ann Nucl Med, 2002, 16(3): 161-168.
4Alatas F, Alatas O, Metintas M, et al. Usefulness of bone markers for detection of bone metastases in lung cancer patients [J]. Clin Biochem, 2002, 35(4): 293-296.
5Kiuchi K, Ishikawa T, Hamaguchi Y, et al. Cross-linked colla- gen C- and N-telopeptides for an early diagnosis of bone metastasis from breast cancer [J]. Oncol Rep, 2002, 9(3): 595-958.
6Ulrich U, Rhiem K, Schmolling J, et al. Cross-linked type I col lagen C- and N-telopeptides in women with bone metastases from breast cancer [J]. Arch Gynecol Obstet, 2001, 264 (4) : 186- 190.
7Martin TJ,Moseley JM.Mechanisms in the skeletal complications of breast cancer.Endocr Relat Cancer,2000,7:271-284.
8Hamaoka T,Madewell JE,Podoloff DA,et al.Bone imaging in metastatic breast cancer.J Clin Oncol,2004,22:2942-2953.
9Wojtacki J,Kruszewski WJ,Sliwinska M,et al.Elevation of serum CA15-3 antigen:an early indicator of distant metastasis from breast cancer.Retrospective analysis of 733 cases.Przegl Lek,2001,58:498-503.
10Garnero P,Ferreras M,Karsdal MA,et al.The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation.J Bone Miner Res,2003,18:859-867.
1Yu S, Jiang Z, Zhang L, et ai.Chinese expert consensus statement onclinical diagnosis and treatment of malignant tumor bone metastasisand bone related diseases[J]. Chinese-German J Clin Oncol, 2010,9?1):1-12.
2LiptonA.Implications of bone metastases and the benefits of bone-tar-geted therapy [J].Semin Oncol, 2010,37 (Suppl 2): S15-29.
3TerposE, Kiagia M, Karapanagiotou EM,et ai.The clinical signifi-can-ce of serum markers of bone turnover in NSCLC patients : surveil —lance,management and prognostic implications [J].Anticancer Res,2009,29(5):1651-1657.
4SalemAM, Zohny SF, Abd El-WalabMM, et al. Predictive value o-fosteocalcin and beta-Crosslaps in metastatic breast cancer [J]. ClinBio-chem, 2007, 40(4): 1201-1208.
5akahashiS. Evaluation of cancer -induced bone diseases by bonemetabolicmarker[J]. Clin Calcium, 2006, 16(2) : 581-590.
6KiryowE, Kaminski G.Place of biochemical markers of bone turnoverin guidelines for diagonosis and treatment of osteoporosis [JJ.PolMerkur Lekarski,2008,25(148):386-389.
